Catalyst Event
Merck and Co Inc (MRK) · Other
From Akros U.S. Tech 100 Index (AUT100)
5/29/2026, 12:00:00 AM
Received FDA Breakthrough Therapy designation for calderasib (MK-1084) on May 29, 2026. Medium importance as this designation accelerates the development of a key oncology candidate.
Korean Translation
2026년 5월 29일 비소세포폐암(NSCLC) 환자의 1차 치료를 위한 칼데라십(MK-1084)에 대해 FDA로부터 혁신 치료제 지정을 승인받음.
Related Recent Events
Lumentum Holdings Inc (LITE) · Earnings Release
Lumentum's next earnings release for Q4 2026 is scheduled for August 11, 2026; high importance as a primary volatility driver scheduled.
8/11/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet is scheduled to announce its Q2 2026 earnings results on August 5, 2026 expected. Medium importance estimated as earnings releases typically cause >5% price volatility.
8/5/2026, 12:00:00 AM
Teradyne Inc (TER) · Earnings Release
High importance is estimated as earnings reports typically drive significant volatility; Q2 2026 earnings release with revenue guidance of $1.15B-$1.25B and non-GAAP EPS of $1.86-$2.15 is scheduled.
8/4/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Earnings Release
Market impact is estimated at Medium (>=5%) based on historical earnings volatility; Axon's Q2 2026 earnings report is scheduled.
8/3/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is expected on July 30, 2026. The company guided for net sales between $194.0 billion and $199.0 billion. Low importance is assigned as the market reaction has not yet occurred expected.
7/30/2026, 12:00:00 AM